Browsing: semaglutide

A £2.7m clinical trial will investigate if a weight-loss jab can help patients living with alcohol dependency and obesity, which the NHS said were two of the biggest causes of liver disease

Aug 20 (Reuters) – Celon Pharma’s experimental semaglutide product Reduzek, a generic alternative ‌to Novo Nordisk’s Wegovy and ‌Ozempic, matched the blockbuster weight-loss drugs in an ​early-stage bioequivalence study, the Polish drugmaker said on Thursday

HealthDay News — Semaglutide sustains lower calorie intake for more than a year, even as feelings of hunger gradually return, according to a study published in the August issue of the American Journal of Clinical Nutrition

For more than a decade, GLP-1 treatment for weight loss has required a weekly injection with a pre-filled pen that needed to be stored in the fridge. This acted as a barrier to entry for many potential patients who may be needle-averse or would struggle to stick to the strict storage and administration routine

[Sportschosun Reporter Jang Jong-ho] A large population-based study has found that semaglutide, widely used to treat diabetes and obesity, may significantly reduce the risk of adult-onset seizures

Semaglutide, a diabetes and obesity medication sold under brand names such as Wegovy and Ozempic, has been shown in a large-scale study to significantly reduce the risk of seizures that first occur in adulthood. The findings suggest that semaglutide may help protect brain health. 

GLP-1 medications have garnered global interest for their benefits in weight loss and diabetes management. Growing consumer access to these products is driving innovations in the food and nutrition industries for healthier, nutrient-dense options in smaller portion sizes. 

An average weight loss of 17%, achieved by taking one tablet in the morning every day: this is the data that convinced the European Commission to authorise the marketing of semaglutide 25 mg tablets (Novo Nordisk)

The Indian GLP-1 agonist market has grown into a Rs 2,055 crore segment as of the moving annual total (MAT) ending June 2026, driven by rapid adoption of newer therapies for diabetes and obesity. However, after two years of exceptional expansion, the market is showing early signs of stabilisation as the pace of growth moderates,…

In 2021, Jordan Miller, then an undergraduate student at UT San Antonio, noticed something strange — a sudden and dramatic increase in poison control center calls across the United States seemed to coincide with the FDA approval of semaglutide for weight management